NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

UNCY

Unicycive Therapeutics Inc

Apr 04 • 12:03PM ET

0.5106

Dollar change -0.0794
Percentage change -13.46	%

Healthcare • Biotechnology • USA • NASD

Peers: BTAI RAPT ARDX ANVS CRBP CUE LGVN CAPR CRDF

| Held by: VTI VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.76	Insider Own	17.08%	Shs Outstand	113.84M	Perf Week	-16.84%
Market Cap	61.12M	Forward P/E	0.47	EPS next Y	1.08	Insider Trans	0.00%	Shs Float	86.07M	Perf Month	-7.25%
Income	-43.75M	PEG	-	EPS next Q	-0.06	Inst Own	62.01%	Short Float	1.77%	Perf Quarter	-35.56%
Sales	0.00M	P/S	-	EPS this Y	77.14%	Inst Trans	95.71%	Short Ratio	1.45	Perf Half Y	33.95%
Book/sh	0.07	P/B	7.82	EPS next Y	945.70%	ROA	-186.02%	Short Interest	1.52M	Perf Year	-62.73%
Cash/sh	0.22	P/C	2.34	EPS next 5Y	-	ROE	-2355.27%	52W Range	0.20 - 1.60	Perf YTD	-35.71%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-31.80%	ROI	-579.61%	52W High	-68.09%	Beta	2.11
Dividend TTM	-	Quick Ratio	1.28	Sales past 5Y	-25.80%	Gross Margin	-	52W Low	152.77%	ATR (14)	0.06
Dividend Ex-Date	-	Current Ratio	1.28	EPS Y/Y TTM	52.65%	Oper. Margin	-	RSI (14)	38.42	Volatility	11.83% 9.39%
Employees	22	Debt/Eq	0.10	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.00	Target Price	7.42
Option/Short	No / Yes	LT Debt/Eq	0.02	EPS Q/Q	15.73%	Payout	-	Rel Volume	2.55	Prev Close	0.59
Sales Surprise	-	EPS Surprise	365.11%	Sales Q/Q	-	Earnings	Mar 31 BMO	Avg Volume	1.05M	Price	0.51
SMA20	-14.59%	SMA50	-12.30%	SMA200	-2.18%	Trades		Volume	1,143,331	Change	-13.46%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-04-24	Initiated	Piper Sandler	Overweight	$9

Apr-01-25 07:00AM	Unicycive Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire) -5.03%
Mar-31-25 07:00AM	Unicycive Therapeutics Announces Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire) -6.37%
Mar-26-25 11:59AM	DaVita Stock Declines 1.2% in 3 Months: Here's How to Play (Zacks)
Mar-13-25 07:00AM	Unicycive to Highlight Patient Reported Outcomes Data at Upcoming Medical Meetings Showing Oxylanthanum Carbonate Reduced Pill Burden and Improved Adherence in Treatment of Hyperphosphatemia (GlobeNewswire)
Feb-20-25 07:00AM	Unicycive Therapeutics Announces the Publication of Preclinical Data on Synergies Between Oxylanthanum Carbonate and Tenapanor in American Society of Nephrology Journal Kidney360 (GlobeNewswire)
07:00AM	Loading…
Jan-28-25 07:00AM	Unicycive Therapeutics Announces the Publication of Patient Perspectives on Phosphate Management in the Journal of Nephrological Science (GlobeNewswire) -5.44%
Jan-07-25 07:00AM	Unicycive Therapeutics Announces Publication of Positive Oxylanthanum Carbonate (OLC) Dose Escalation Data in Clinical and Translational Science (GlobeNewswire)
Dec-17-24 07:00AM	Unicycive Therapeutics Announces Publication of Oxylanthanum Carbonate (OLC) Positive Bioequivalence Data in Clinical Therapeutics (GlobeNewswire)
Nov-21-24 07:00AM	Unicycive Therapeutics to Participate in Two Upcoming Investor Conferences Including a Fireside Chat at the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
Nov-13-24 07:15AM	Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Nov-11-24 07:00AM	Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis (GlobeNewswire) -9.63%
Oct-28-24 07:03AM	Unicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate (OLC) and UNI-494 at the American Society of Nephrology (ASN) Kidney Week 2024 (GlobeNewswire) +20.24%
Oct-16-24 04:35PM	Unicycive Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on October 17, 2024 (GlobeNewswire) +11.39%
11:43AM	Results of Phase I trial shed positive light on UNI-494 for acute kidney injury (Clinical Trials Arena)
Oct-14-24 07:03AM	Unicycive Therapeutics Announces Late-Breaker Poster Presentation on Oxylanthanum Carbonate (OLC) at the American Society of Nephrology (ASN) Kidney Week 2024 (GlobeNewswire)
07:03PM	Loading…
Oct-11-24 07:03PM	Octagon Capital Advisors LP Acquires New Stake in Unicycive Therapeutics Inc (GuruFocus.com)
Oct-09-24 07:03AM	Unicycive Therapeutics Successfully Completes UNI-494 Phase 1 Study in Healthy Volunteers (GlobeNewswire)
Sep-24-24 07:03AM	Unicycive Therapeutics to Participate in a Fireside Chat at the Virtual Lytham Partners Fall 2024 Investor Conference on October 1, 2024 (GlobeNewswire)
Sep-20-24 08:35AM	Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing (GlobeNewswire) +6.98%
Sep-16-24 12:07PM	Life Sciences Virtual Investor Forum Agenda Announced for September 19th (GlobeNewswire)
07:03AM	Unicycive Therapeutics to Present at the Virtual Life Sciences Investor Forum on September 19, 2024 (GlobeNewswire)
Sep-05-24 07:03AM	Unicycive Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Sep-03-24 07:03AM	Unicycive Therapeutics Announces Submission of the New Drug Application (NDA) to the U.S. FDA for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis (GlobeNewswire) -5.89%
Aug-26-24 07:03AM	Unicycive Therapeutics to Present Three Posters at the American Society of Nephrology (ASN) Kidney Week 2024 (GlobeNewswire)
Aug-14-24 07:10AM	Unicycive Announces Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) +34.03%
Jul-17-24 07:03AM	Unicycive Therapeutics Granted Patent on UNI-494 to Treat Acute Kidney Injury by the United States Patent and Trademark Office (USPTO) (GlobeNewswire) -6.99%
Jul-11-24 07:03AM	Unicycive Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 3rd Annual Kidney Virtual Conference (GlobeNewswire)
Jul-10-24 07:03AM	Unicycive Therapeutics Announces Initial Positive Patient Satisfaction Findings from Pivotal Clinical Trial of Oxylanthanum Carbonate (OLC) (GlobeNewswire)
Jul-01-24 07:03AM	Unicycive Therapeutics Joins Russell Microcap Index (GlobeNewswire) +7.76%
Jun-25-24 07:30AM	Unicycive Therapeutics Achieves Study Objective in Oxylanthanum Carbonate (OLC) Pivotal Clinical Trial (GlobeNewswire) -26.76%
07:03AM	Loading…
May-28-24 07:03AM	Unicycive Therapeutics Delivers Multiple Presentations on Oxylanthanum Carbonate (OLC) and UNI-494 at the European Renal Association Congress (GlobeNewswire) -11.65%
May-23-24 07:03AM	Unicycive Therapeutics to Participate in a Fireside Chat at the Lytham Partners Spring 2024 Investor Conference (GlobeNewswire)
May-15-24 07:03AM	Unicycive Therapeutics Presents Bioequivalence Data on Oxylanthanum Carbonate (OLC) at the National Kidney Foundation Spring Clinical Meeting (GlobeNewswire)
May-13-24 10:53PM	UNCY Stock Earnings: Unicycive Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
04:16PM	Unicycive Announces First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-01-24 07:00AM	3 Top Penny Stocks to Buy for Explosive Returns: April Edition (InvestorPlace)
Apr-29-24 01:37PM	These 2 Strong Buy Penny Stocks Could Rally to $9, Says Piper Sandler (TipRanks) +18.45%
Apr-10-24 07:03AM	Unicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference (GlobeNewswire)
Mar-28-24 10:53PM	UNCY Stock Earnings: Unicycive Therapeutics Misses EPS for Q4 2023 (InvestorPlace) -5.48%
04:15PM	Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-25-24 07:03AM	Unicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association Congress (GlobeNewswire)
Mar-14-24 07:03AM	Unicycive Announces $50 Million Private Placement (GlobeNewswire)
Mar-13-24 07:03AM	Unicycive Therapeutics Delivers Both an Oral and Poster Presentation on UNI-494 at the AKI and CRRT Conference (GlobeNewswire)
Mar-07-24 04:12PM	Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC) (GlobeNewswire)
Mar-04-24 07:03AM	Unicycive Therapeutics Announces Orphan Drug Designation Granted for UNI-494 by the U.S. Food and Drug Administration for the Prevention of Delayed Graft Function in Kidney Transplant Patients (GlobeNewswire) -6.88%
Feb-14-24 07:03AM	Unicycive Therapeutics to Present Two Posters on Oxylanthanum Carbonate (OLC) at the Upcoming National Kidney Foundation Spring Clinical Meeting (GlobeNewswire) +10.48%
Jan-29-24 07:03AM	Unicycive Therapeutics Announces Both an Oral and Poster Presentation to be Delivered on UNI-494 at the Upcoming AKI and CRRT Conference (GlobeNewswire) +7.43%
Jan-24-24 09:39AM	Unicycive (UNCY) Up on Positive Hyperphosphatemia Study Update (Zacks)
Jan-23-24 07:03AM	Unicycive Therapeutics Issues Shareholder Letter to Highlight Corporate Progress and Key Upcoming Milestones (GlobeNewswire) +18.29%
Dec-18-23 07:03AM	Unicycive Therapeutics Announces Enrollment of First Patient in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC) in Patients with Chronic Kidney Disease on Dialysis (GlobeNewswire)
Nov-29-23 07:03AM	Unicycive Therapeutics to Participate in Two Investor Conferences in December 2023 (GlobeNewswire) -5.37%
Nov-14-23 04:15PM	Unicycive Announces Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Oct-23-23 07:03AM	Unicycive Therapeutics Reaches Alignment with the FDA on Path to File New Drug Application for Oxylanthanum Carbonate (OLC) (GlobeNewswire) -7.91%
Sep-06-23 07:03AM	Unicycive Therapeutics Strengthens Board of Directors with Appointment of Sara Kenkare-Mitra, PhD (GlobeNewswire)
Aug-29-23 07:03AM	Unicycive Therapeutics Featured on Nasdaq Amplify Issuer Spotlight Series (GlobeNewswire)
Aug-14-23 05:36PM	Unicycive Announces Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) -7.37%
Jul-21-23 04:30PM	CORRECTION FROM SOURCE: 60 Degrees Pharmaceuticals and Unicycive Therapeutics Interviews to Air on Bloomberg TV on the RedChip Money Report(R) (ACCESSWIRE)
09:00AM	60 Degrees Pharmaceuticals and Unicycive Therapeutics Interviews to Air on Bloomberg TV on the RedChip Money Report(R) (ACCESSWIRE)
Jul-20-23 07:03AM	Unicycive Therapeutics to Participate in the H.C. Wainwright 2nd Annual Kidney Conference (GlobeNewswire)
Jul-18-23 07:03AM	Unicycive Therapeutics Announces Publication of Positive Comparison of Oxylanthanum Carbonate to Commercially Available Phosphate Binders in the American Journal of Nephrology (GlobeNewswire)
Jun-29-23 05:04PM	Unicycive Therapeutics Provides Regulatory Update on Lanthanum Dioxycarbonate Program (GlobeNewswire) -22.42%
Jun-16-23 07:38AM	Unicycive to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET (GlobeNewswire) -7.59%
Jun-09-23 09:00AM	Unicycive Therapeutics, Inc. and Alarum Technologies Ltd. Interviews to Air on Bloomberg TV on the RedChip Money Report® (ACCESSWIRE) +12.90%
May-17-23 06:03AM	Unicycive Therapeutics, Inc.'s (NASDAQ:UNCY) Profit Outlook (Simply Wall St.)
May-16-23 08:29AM	Unicycive Announces First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Apr-24-23 07:00AM	Unicycive Announces Acceptance of Multiple Datasets to Be Presented at the European Renal Association Congress (GlobeNewswire)
Mar-31-23 07:00AM	Unicycive Announces Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire) +11.70%
Mar-08-23 06:04AM	Shareholders have faith in Unicycive Therapeutics (NASDAQ:UNCY) as stock climbs 36% in past week, taking one-year gain to 99% (Simply Wall St.) +8.00%
Mar-07-23 09:00AM	The Unmet Need For Innovative And Effective Treatments For Kidney Disease: Acute Kidney Injury (News Direct) +20.97%
Mar-06-23 07:00AM	Unicycive Announces up to $130 Million Financing to Commercialize and Launch Investigational New Drug Renazorb (GlobeNewswire) +153.06%
Mar-03-23 09:15AM	The Silent Killer: The Impact Of Kidney Disease On Patients And Their Caregivers (News Direct)
Feb-27-23 07:00AM	Unicycive to Highlight Potential of UNI-494 to Restore Mitochondrial Function and Reduce Oxidative Stress at Two Upcoming Medical and Scientific Meetings (GlobeNewswire)
Feb-17-23 10:35AM	Unicycive: The Company Developing Key Kidney Therapies (News Direct)
Feb-06-23 09:59AM	Unicycive: This Biotech Company Receives Promising Results From New Trial (News Direct)
Feb-02-23 08:30AM	Unicycive Announces Exclusive License and Development Agreement with Lotus for Renazorb in the Republic of Korea (GlobeNewswire) -7.05%
Jan-23-23 07:00AM	Unicycive Announces Acceptance of Three Abstracts for Presentation at the National Kidney Foundations Spring Clinical Meetings (GlobeNewswire) +5.34%
Jan-05-23 07:00AM	Unicycive Announces Acceptance of Four Abstracts for Presentation at the World Congress of Nephrology 2023 (GlobeNewswire) -8.98%
Dec-29-22 11:31AM	Unicycive Announces Termination of At-The-Market Offering of Shares of Common Stock (GlobeNewswire) +12.00%
Dec-28-22 09:21AM	Unicycive Shares Jump As Renazorb Achieves Primary Endpoint In Bioequivalence Study (Benzinga) -25.37%
08:30AM	Unicycive Achieves Primary Endpoint in Pivotal Bioequivalence Study of Renazorb (GlobeNewswire)
Dec-22-22 07:00AM	Unicycive Issued Notice of Acceptance to Initiate Phase 1 Study of UNI-494 Following Review of Clinical Trial Application by the Medicines and Healthcare Products Regulatory Agency in the United Kingdom (GlobeNewswire)
Dec-09-22 08:00AM	Unicycive Therapeutics, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R) (ACCESSWIRE)
Nov-28-22 07:00AM	Unicycive to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-21-22 10:32AM	Unicycive Therapeutics' Geographic Atrophy Candidate Shows Improved Contrast Vision In Animal Studies (Benzinga)
07:00AM	Unicycive Reports Key Findings of UNI-494 Efficacy in Preclinical Animal Model of Geographic Atrophy (GlobeNewswire)
Nov-14-22 07:00AM	Unicycive Announces Third Quarter Financial Results and Provides Business Update (GlobeNewswire) -5.59%
Nov-10-22 07:00AM	Unicycive Completes Enrollment of Pivotal Bioequivalence Study for RENAZORB (lanthanum dioxycarbonate), an Investigational Treatment for Hyperphosphatemia in Chronic Kidney Disease (CKD) Patients on Dialysis (GlobeNewswire) +9.70%
Nov-08-22 09:00AM	Unicycives Doug Jermasek, EVP-Corporate Development Discusses the Importance of Medication Compliance and the Issues with Pill Burden (News Direct)
Oct-26-22 08:04AM	Unicycive to Showcase Pipeline of Innovative Product Candidates at American Society of Nephrologys Kidney Week 2022 (GlobeNewswire)
Oct-12-22 08:00AM	Mighty Mitochondria: This Company is Developing A Novel Drug for Kidney Disease By Targeting The Powerhouse Of Human Cells (News Direct)
Sep-29-22 07:00AM	Unicycive Therapeutics to Present at Roth Inaugural Healthcare Opportunities Conference (GlobeNewswire)
Sep-23-22 09:11AM	How One Company Plans To Help Battle A Silent Killer Globally Through Its New Kidney Disease Medication (News Direct) -5.33%
Sep-07-22 07:00AM	Unicycive Reports Key Findings of UNI-494 Efficacy in Preclinical Animal Model of Acute Kidney Injury (AKI) (GlobeNewswire) +6.59%
Sep-06-22 07:00AM	Unicycive Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire) +5.80%
Aug-24-22 07:00AM	Unicycive Announces Multiple Abstracts Selected for Presentation at American Society of Nephrologys Kidney Week 2022 (GlobeNewswire)
Aug-15-22 06:03PM	Unicycive Announces Second Quarter Financial Results and Provides Business Update (GlobeNewswire)
Jul-26-22 07:00AM	Unicycive Reports Key Findings from Independent Renal Dietitian Survey (GlobeNewswire) -6.93%
Jul-20-22 07:12AM	Unicycive Reports Key Findings from Market Research with Nephrologists (GlobeNewswire)
Jul-18-22 07:48AM	Unicycive Inks Licensing Pact For Its Kidney Disease Candidate In China (Benzinga) +9.84%
07:00AM	Unicycive Announces Exclusive License and Development Agreement with Lees Pharmaceutical Holdings Limited for Renazorb in China and Certain Other Asian Markets (GlobeNewswire)

Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. Its products include UNI-494, Renazorb, and UNI-220. The company was founded by Shalabh Gupta on August 18, 2016 and is headquartered in Los Altos, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

UNCY

Unicycive Therapeutics Inc

Upgrade your FINVIZ experience